- Home
- CAAP vs TERN Comparison
CAAP vs TERN Comparison
Compare CAAP & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAAP | TERN |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.8B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CAAP | TERN |
|---|---|---|
| Price | $24.29 | $52.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $26.73 | ★ $45.22 |
| AVG Volume (30 Days) | 236.4K | ★ 6.3M |
| Earning Date | 05-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.80 | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | $26.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.36 | $2.82 |
| 52 Week High | $30.50 | $53.19 |
Technical Indicators
Market Signals| Indicator | CAAP | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 74.22 |
| Support Level | $23.83 | $52.42 |
| Resistance Level | $26.78 | $53.19 |
| Average True Range (ATR) | 0.82 | 0.07 |
| MACD | -0.13 | -0.32 |
| Stochastic Oscillator | 5.60 | 91.89 |
Price Performance
Historical ComparisonAbout CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.